Leydig, Voit & Mayer, LTD. Intellectual Property Law

Pharmaceutical and Chemical Technologies

At Leydig, Voit & Mayer, we believe proactive counseling and patent management are key to helping clients leverage their pharmaceutical developments and advances. Our expertise in the pharmaceutical industry enables us to effectively advise clients on strategies reflecting the newest interpretation of case law.

Services include litigation, conducting interference proceedings, providing opinions, and negotiating licenses. We also prosecute and manage (as part of an integrated business approach) patent portfolios in diverse pharmaceutical areas, such as protease inhibitors, organic synthesis, polymeric membranes and small molecule pharmaceuticals.

As an evolving industry, the chemical arts encompass a broad array of separate technology fields. At Leydig, Voit & Mayer, our attorneys are experienced in helping clients in areas such as nanotechnology, drug delivery and formulation, polymer technology, chiral separations, supercritical fluids and other developing technologies.

We have experience in prosecuting and managing patents in the major areas of chemical technology and chemical engineering. In addition, we have successfully litigated intellectual property matters in diverse areas of the chemical arts.

Leydig has a substantial practice in the area of pharmaceuticals. A significant aspect of that practice involves representing clients in the generic drug industry. Leydig has a dedicated team of professionals with extensive experience and depth in representing pharmaceutical companies with legal issues arising under the Hatch-Waxman Act. Our team’s approach is vital to the success of our clients. Subtle differences in presentation and perspectives can often lead to profound differences in outcome, and we have the experience to review each matter with this in mind to identify those issues that can critically impact a client’s case. We can then develop the most favorable legal position available to our client. Our pharmaceutical team also prides itself on keeping our firm and our clients on the cutting edge of the ever-changing world of legal developments, which can directly impact our client’s products.

For decades, and with over 50 Hatch-Waxman/ANDA litigations, our firm has been paving the way for pharmaceutical companies to obtain approval for generic versions of branded drugs ranging from niche-market drugs to blockbusters.